Loading…

Synektik SASNT.WACompetitor analysis, valuation and peers

Poland · PLN·Health Care›Medical Specialties
Momentum weak 38
Mkt cap
$662M
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$2.38M
20-day average traded
Fwd P/E
13.8×
forward earnings
ROIC−WACC
+83.9 pp
WACC 10.1%
Hurdle
-47 pp
Req g minus delivered
Next earnings
209 days
15 Jun 2027
Close · PLNPLN 312.00
1D-2.2%
1W-5.2%
1M-8.9%
3M-12.6%
6M+10.4%
YTD+24.3%
1Y+35.1%
ATR %3.8%
52w lowhigh21.7% off high

What Synektik does

No business profile yet.

Synektik at a glance

Size Synektik (SNT.WA) is a Poland Health Care company (Medical Specialties) with a market value of $662M, the 51st largest of 82 Poland companies the cockpit tracks. Shares closed at PLN 312.00 on 18 Nov 2026.

Performance Over six months the shares gained 10.4%, against -10.5% for the median peer and +14.0% for the Poland market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 31.9% over the last twelve months (peer median +16.2%); the operating margin is 23.7% (peer median 12.6%).

Valuation It trades at 13.8× forward earnings against a peer median of 27.9× (4th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +48%, so the hurdle is -47 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 83.9 points above its cost of capital (10.1% WACC).

Next results Next results expected around 15 Jun 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026SNT.WA 109Peer median 91
Six months, rebased to 100: Synektik against the median of its 20 peers (local-currency closes).

Synektik financials

Reported figures in PLN; fiscal year ends 2026-09-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenuePLN 899MPLN 899MPLN 682MPLN 624MPLN 447M
Revenue growth—+32%+9%+40%—
Gross profitPLN 317MPLN 317MPLN 244MPLN 190MPLN 132M
EBITDAPLN 234MPLN 234MPLN 179MPLN 143MPLN 84.0M
Net incomePLN 414MPLN 414MPLN 103MPLN 82.6MPLN 52.5M
Free cash flowPLN 145MPLN 145MPLN 58.6MPLN 43.3MPLN 84.8M
Capital expenditurePLN 25.7MPLN 25.7MPLN 17.4MPLN 44.9MPLN 9.68M
Total debtPLN 40.3MPLN 40.3MPLN 40.9MPLN 24.5MPLN 18.7M

Quarterly statements and history in the cockpit →

Synektik competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%300326QDEL0028761789DCTH491000688389688085185830123415017575688410XVIVO301122NANMEDISGHTSNT.WA6-month return →1-month return →
Up and to the right = strong over both horizons. Synektik is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×200×300326QDEL0028761789DCTH688389688085185815017575688410300622301122NANSNT.WARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Synektik is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%3003260028761789DCTH68838968808518583012341501688410XVIVONANSNT.WAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Synektik is the large dot.

Synektik competitors and peer comparison

How Synektik compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Synektik against its 20 peers (data as of 18 Nov 2026)
MeasureSNT.WAPeer medianRank in peer set
1-month return-8.9%-1.9%7th lowest of 21
6-month return+10.4%-10.5%7th highest of 21
Distance from 52-week high-21.7%-33.8%8th highest of 21
Revenue growth (TTM)+31.9%+16.2%5th highest of 21
Operating margin23.7%12.6%5th highest of 21
Forward P/E13.8×27.9×4th cheapest of 17
Growth the price implies (Req g, 7 yrs)0.2%8.4%8th least demanding of 17
Growth delivered (Del g)+47.5%+13.7%2nd highest of 17
Hurdle (Req g minus delivered)-47.3 pp-10.4 pp2nd least demanding of 17
ROIC minus cost of capital+83.9 pp+3.8 pp2nd highest of 21
EV / EBITDA11.1×14.9×4th cheapest of 10
Net debt / EBITDA-0.2×-1.0×2nd most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Synektik SNT.WAPoland$662M+10%+32%24%13.8×0.2%+47.5%
Shanghai Kinetic Medical 300326.SZChina$662M-10%-28%17%26.0×6.6%-1.9%
QuidelOrtho QDELUnited States$657M-20%-5%-2%10.7×n/an/a
Shenzhen Sunnypol Optoelectornics 002876.SZChina$680M-9%+29%5%39.0×10.1%+14.2%
AK Medical 1789.HKHong Kong$642M-23%+16%26%10.5×-11.5%+6.7%
Delcath Systems DCTHUnited States$685M+75%+38%5%358.9×33.4%+120.2%
Livsmed 491000.KSSouth Korea$687M-47%+89%-77%n/an/an/a
Shenzhen Lifotronic Technology 688389.SSChina$692M-14%+14%13%29.9×11.6%+13.3%
Shanghai Sanyou Medical 688085.SSChina$692M-23%+15%4%50.0×29.0%+6.8%
Beijing Chunlizhengda Medical Instruments 1858.HKHong Kong$631M-28%-9%31%8.5×-9.5%+1.5%
SunMax Biotechnology 4728.TWOTaiwan$630M0%+19%51%n/a-2.6%+18.8%
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$697M+148%-14%3%n/a31.8%-0.6%
Shanghai INT Medical Instruments 1501.HKHong Kong$700M-25%+35%21%15.9×-3.3%+23.5%
Japan Lifeline 7575.TJapan$703M+34%+6%19%14.5×-9.5%+2.9%
SWS Hemodialysis Care 688410.SSChina$706M-11%+31%19%23.5×16.2%+25.9%
Doctorglasses Chain 300622.SZChina$710M-22%+6%14%22.8×-3.4%+15.7%
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%53.1×35.9%+35.2%
Caina Technology 301122.SZChina$721M+36%+61%0%55.4×n/an/a
Nanosonics NAN.AXAustralia$599M-4%+3%7%98.6×35.3%+6.7%
Medistim MEDI.OLNorway$599M+32%+19%29%31.8×-1.2%+14.5%
Sight Sciences SGHTUnited States$599M+122%+16%-30%n/an/an/a

Questions

Which companies are Synektik's closest peers?
The cockpit's peer set: Shanghai Kinetic Medical (300326.SZ), QuidelOrtho (QDEL), Shenzhen Sunnypol Optoelectornics (002876.SZ), AK Medical (1789.HK), Delcath Systems (DCTH), Livsmed (491000.KS), Shenzhen Lifotronic Technology (688389.SS), Shanghai Sanyou Medical (688085.SS).
Is Synektik expensive compared with its peers?
On forward p/e it trades at 13.8× against a peer median of 27.9×, 4th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +48%, so the hurdle is -47 pp: the price already allows for a slowdown.
How has Synektik stock performed?
Over six months to 18 Nov 2026 the shares returned +10.4% against -10.5% for the median peer; over one year +35.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.